Top Gainers Today Fueled by Buyouts Earnings Beats and Analyst Upgrades

 Top.Gainers
 
  Top.Gainers
 
Follow  Message
 
 
 
Top.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
 

•  05 Aug 2025
 

•   AIP  
   
  -23.92%
•   YMAB  
   
  0.00%

Y-Mabs Therapeutics made waves in the biotech space with an astonishing 103% jump after announcing its acquisition by SERB Pharmaceuticals in a take-private deal. The acquisition, which includes the company’s flagship cancer drug DANYELZA, strengthens SERB rare oncology portfolio. With volume surging to 20 million, well above the average of 193K this buyout clearly caught traders and institutions off guard.

AIP shot up 37% today as traders piled in ahead of AMD highly anticipated earnings release. Adding to the excitement, Arteris announced that AMD has licensed its FlexGen network-on-chip (NoC) IP for next-gen chip designs, critical tech for AI workloads. The partnership not only validates Arteris innovation but also places it squarely in the AI infrastructure supply chain.

Shattuck Labs soared 33% after it unveiled a $103 million oversubscribed private placement. The fresh capital is expected to fund Phase 2 trials for SL-325, a potential treatment for inflammatory bowel disease and autoimmune conditions. That’s big news for a biotech stock trading under $1 just yesterday. With volume exploding to over 93 million shares, far exceeding its 368K average traders clearly see a second wind in STTK's clinical pipeline.

Helios Technologies gained 31% following a flurry of analyst activity that tipped sentiment in its favor. In recent weeks, analysts at KeyBanc and Stifel upgraded the stock and raised their price targets, citing improved fundamentals and stronger growth outlooks. Although Baird issued a downgrade, the consensus remains optimistic with average targets pointing north of $43. With Helios trading near $48, the market seems to be looking even further ahead, perhaps pricing in a broader industrial recovery.

Lemonade bounced nearly 30% after delivering Q2 results that topped expectations. The insurtech firm reported a smaller-than-expected GAAP loss of $0.60 per share and beat revenue estimates by $3.3 million. Investors were especially encouraged by strong IFP (in-force premium) guidance, which suggests growth is not just steady it’s accelerating. Volume was nearly six times the daily average, signaling renewed interest in this former high-flyer that's been trying to claw back relevance in a competitive fintech space.

While all five names made impressive moves today, $AIP stands out with the strongest combination of thematic momentum (AI), a high-profile licensing deal with AMD, and earnings hype still ahead. For traders seeking near-term opportunity, this ticker checks the boxes for both growth narrative and catalyst potential. However, for those who prefer the certainty of a finalized acquisition, $YMAB still offers solid risk/reward—especially if arbitrage spreads widen. As always, stay sharp and trade the trend.